Lab Notes: Inovio expands Covid-19 vaccine trials; Janssen makes Stelara label expansion bid
This week's life sciences industry roundup includes the latest news from Inovio, Janssen, NRx Pharmaceuticals and more. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 15, 2021 Category: American Health Authors: John George Source Type: news

Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associa...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque p...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cardiovascular Safety of Biologics Targeting IL-12 or IL-23 Cardiovascular Safety of Biologics Targeting IL-12 or IL-23
Do the biologics briakinumab and ustekinumab, which target interleukin-12 and IL-23 in the treatment of psoriasis, increase the risk of cardiovascular disease?American Journal of Clinical Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 24, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being pr...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Ustekinumab in Infliximab-refractory Pediatric UC Ustekinumab in Infliximab-refractory Pediatric UC
This study evaluated the efficacy of ustekinumab following failure of prior biologics in pediatric ulcerative colitis.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Guidelines: Management of Moderate to Severe Crohn's Disease Guidelines: Management of Moderate to Severe Crohn's Disease
The AGA released guidelines for adult outpatients with moderate to severe Crohn's disease, strongly recommending induction and maintenance therapy with anti-TNF-alpha agents or ustekinumab.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - June 16, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, June 2, 2021 – Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA® (guselkumab), including data from the first study evaluating a selective IL-23 inhibitor in adult patients with active PsA, all of whom had demonstrated inadequate response or intolerance to TNFi.1 In the COSMOS Phase 3b study, significantly higher proportions of patients treated with TREMFYA showed joint symptom improvement and complete skin clearance versus placebo at week 24 in this true TNFi-IRa patient population, which is often more...
Source: Johnson and Johnson - June 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

SEAVUE: Ustekinumab vs Adalimumab for Crohn's Disease SEAVUE: Ustekinumab vs Adalimumab for Crohn's Disease
For biologic-naive adults with moderate to severe Crohn's disease, treatment with either adalimumab or ustekinumab leads to similar outcomes, according to results of the head-to-head SEAVUE trial.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 28, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve p...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

VENUS: Ustekinumab Superior to Vedolizumab for Refractory Crohn's VENUS: Ustekinumab Superior to Vedolizumab for Refractory Crohn's
A study directly compares two biologic agents among patients with Crohn's disease who failed previous anti-TNF therapy.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 21, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

VENUS: Ustekinumab Appears Superior to Vedolizumab for Crohn's VENUS: Ustekinumab Appears Superior to Vedolizumab for Crohn's
A retrospective analysis compares two biologic agents among patients with Crohn's disease who failed previous anti-TNF therapy.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 21, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

New Phase 3 Data Showed First-in-Class TREMFYA ® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust Joint Symptom Improvement Through 52 Weeks in Active Psoriatic Arthritis (PsA)
SPRING HOUSE, PENNSYLVANIA, April 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new Phase 3 data which showed TREMFYA® (guselkumab) sustained durable, complete skin clearance rates in a majority of adults with moderate to severe plaque psoriasis (PsO) through five years (252 weeks), a and improved disease activity and axial symptoms in adults with active psoriatic arthritis (PsA) through one year (52 weeks).1,2,3 These data are being presented at the American Academy of Dermatology Virtual Meeting Experience 2021, where Janssen will present a total of 22 abstracts. TREMF...
Source: Johnson and Johnson - April 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Reports 2021 First-Quarter Results
New Brunswick, N.J. (April 20, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021. “Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices,” said Alex Gorsky, Chairman and Chief Executive Officer. “The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000...
Source: Johnson and Johnson - April 20, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

New Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
SPRING HOUSE, PENNSYLVANIA, March 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis...
Source: Johnson and Johnson - March 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Bimekizumab Superior to Ustekinumab for Plaque Psoriasis
FRIDAY, Feb. 5, 2021 -- For moderate-to-severe plaque psoriasis, bimekizumab is more efficacious than ustekinumab and placebo, according to a study published in the Feb. 6 issue of The Lancet. Kristian Reich, M.D., from the University Medical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 5, 2021 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world a...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Ustekinumab for Ulcerative Colitis Through 2 Years of Therapy Ustekinumab for Ulcerative Colitis Through 2 Years of Therapy
This long-term extension study assessed the efficacy and safety of one additional year of ustekinumab maintenance treatment in patients originally manifesting moderate-to-severe ulcerative colitis.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Ustekinumab for Plaque Psoriasis in Pediatric Patients Ustekinumab for Plaque Psoriasis in Pediatric Patients
Ustekinumab is currently approved for the treatment of moderate-to-severe plaque psoriasis in adolescents and adults; is it safe for younger patients?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 12, 2020 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 ...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Ustekinumab May Trigger Acute CV Events Early in Treatment Ustekinumab May Trigger Acute CV Events Early in Treatment
Initiating treatment with ustekinumab, an IL-12/23-targeting monoclonal antibody, may trigger early severe cardiovascular events in susceptible patients.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 18, 2020 Category: Dermatology Tags: Dermatology News Source Type: news

FDA Approves Stelara (ustekinumab) for Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
HORSHAM, Pa., July 30, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Stelara (ustekinumab) as a treatment... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 30, 2020 Category: Drugs & Pharmacology Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
SPRING HOUSE, PENNSYLVANIA, June 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to lack of efficacy in SLE.The decision is based on data from a pre-planned interim efficacy analysis. Interim safety findings were consistent with the known safety profile of STELARA, and no new safety signals were identified. Investigators, study participants and health authorities have been informed of the decision. The company intends to thoroughly analyze the totality of...
Source: Johnson and Johnson - June 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
SPRING HOUSE, Pa., June 26, 2020 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Ery... Biopharmaceuticals Janssen Pharmaceutical, Johnson & Johnson, STELARA, ustekinumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 26, 2020 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Reports 2020 First-Quarter Results:
New Brunswick, N.J. (April 14, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2020. The Company also announced earlier today that its Board of Directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. At the new rate, the indicated dividend on an annual basis is $4.04 per share compared to the previous rate of $3.80 per share. “With Johnson & Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic,” sai...
Source: Johnson and Johnson - April 14, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Ustekinumab reduces costs and utilisation in US patients with Crohn's disease
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 31, 2020 Category: Drugs & Pharmacology Source Type: news

FDA OKs Ustekinumab (Stelara) for Moderate to Severe UC FDA OKs Ustekinumab (Stelara) for Moderate to Severe UC
Ustekinumab was more effective than placebo for inducing and maintaining remission and promoting mucosal healing in a study of adults with moderately to severely active ulcerative colitis.FDA Approvals (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - October 21, 2019 Category: Internal Medicine Tags: Gastroenterology News Alert Source Type: news

Janssen Announces FDA Approval of Stelara (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
HORSHAM, PENNSYLVANIA, October 21, 2019– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the U.S. Food and Drug Administration’s (FDA) approval of Stelara (ustekinumab) for the treatment of adult patients... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 21, 2019 Category: Drugs & Pharmacology Source Type: news

Janssen Announces U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative
In the Phase 3 pivotal trial, more than 40 percent of patients receiving STELARA subcutaneous (SC) injections every 8 weeks were in clinical remission at one year and not taking corticosteroidsSTELARA is the first and only approved treatment for ulcerative colitis to demonstrate improvement of the colon as measured by a novel histologic-endoscopic mucosal improvement endpoint (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 21, 2019 Category: Pharmaceuticals Source Type: news

Vedolizumab Beats Adalimumab for Ulcerative Colitis Remissions
WEDNESDAY, Sept. 25, 2019 -- In moderate-to-severe ulcerative colitis, vedolizumab is superior to adalimumab for achieving clinical remission and endoscopic improvement, but not corticosteroid-free clinical remission, and ustekinumab is superior to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 25, 2019 Category: Pharmaceuticals Source Type: news

Sarcoid-Like Ustekinumab Induced Granulomatous Reaction Sarcoid-Like Ustekinumab Induced Granulomatous Reaction
This patient presented with a rare disseminated sarcoid-like reaction while undergoing treatment with the monoclonal antibody ustekinumab for refractory psoriasis.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

ustekinumab (Stelara)
Title: ustekinumab (Stelara)Category: MedicationsCreated: 1/5/2010 12:00:00 AMLast Editorial Review: 8/5/2019 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - August 5, 2019 Category: Dermatology Source Type: news

Risankizumab vs. Ustekinumab for Plaque Psoriasis Risankizumab vs. Ustekinumab for Plaque Psoriasis
A recent head-to-head study compared risankizumab with ustekinumab for treatment of moderate-to-severe chronic plaque psoriasis. This critical assessment examines the validity of the results.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Infection Risk Lower With Certain Psoriasis Treatments
MONDAY, May 13, 2019 -- For patients with psoriasis treated with systemic medications, the risk for serious infection is reduced for new users of apremilast, etanercept, and ustekinumab versus methotrexate, according to a study published online May... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 13, 2019 Category: Pharmaceuticals Source Type: news

HLA-C*06:02 Negativity Shouldn't Bar Ustekinumab Treatment for Psoriasis HLA-C*06:02 Negativity Shouldn't Bar Ustekinumab Treatment for Psoriasis
Although being positive for the HLA-C*06:02 genotype is associated with a better response to ustekinumab therapy in patients with plaque psoriasis, those with negative findings also do well, according to Dutch researchers.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 30, 2019 Category: Pathology Tags: Dermatology News Source Type: news

Drug Survival Rates Highest for Ustekinumab for Pediatric Psoriasis
THURSDAY, March 28, 2019 -- In real-life conditions, drug survival rates are higher for ustekinumab than for adalimumab and etanercept for all treatments and types of psoriasis in children, according to a study published online March 18 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2019 Category: Pharmaceuticals Source Type: news

Brodalumab as an Alternative to Ustekinumab in Psoriasis Brodalumab as an Alternative to Ustekinumab in Psoriasis
Is brodalumab effective in treating moderate-to-severe psoriasis in patients who do not achieve adequate response with ustekinumab?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 18, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Medical News Today: Stelara vs. Humira: What's the difference?
Stelara and Humira are two biologics that help treat immune conditions, such as psoriatic arthritis and Crohn ’s disease. In this article, we look at the similarities and differences in their effects, benefits, and risks. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 14, 2019 Category: Consumer Health News Tags: Rheumatology Source Type: news

New Phase 3 Stelara ® (Ustekinumab) Data Show Positive Results as Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 11, 2019 Category: Pharmaceuticals Source Type: news

J & J Raises U.S. Prices on Around Two Dozen Drugs J & J Raises U.S. Prices on Around Two Dozen Drugs
Johnson& Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara (ustekinumab), prostate cancer drug Zytiga (abiraterone) and blood thinner Xarelto (rivaroxaban), all among its top-selling products.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 14, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

J & amp;J raises U.S. drug prices
Johnson& Johnson raised U.S. prices on around two dozen drugs, including psoriasis treatment, Stelara, prostate cancer drug, Zytiga, and blood thinner, Xarelto. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 11, 2019 Category: Pharmaceuticals Source Type: news

J & J raises U.S. drug prices
Johnson& Johnson raised U.S. prices on around two dozen drugs, including psoriasis treatment, Stelara, prostate cancer drug, Zytiga, and blood thinner, Xarelto. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 11, 2019 Category: Pharmaceuticals Source Type: news

J & J raises U.S. prices on around two dozen drugs
Johnson& Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among its top-selling products. (Source: Reuters: Health)
Source: Reuters: Health - January 10, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Noninfectious Pneumonia Tied to Ustekinumab Use Noninfectious Pneumonia Tied to Ustekinumab Use
Treatment with ustekinumab (Stelara, Janssen Biotech) may be associated with noninfectious pneumonia, according to a report by the U.S. Food and Drug Administration (FDA).Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 28, 2018 Category: Intensive Care Tags: Pulmonary Medicine News Source Type: news

Two-Drug Regimen Fails to Stem Psoriasis Relapse
(MedPage Today) -- Study looks at costimulatory blockade with abatacept after stopping ustekinumab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 18, 2018 Category: Primary Care Source Type: news

Minimal Disease Activity and Acceptable Symptom State in PsA Minimal Disease Activity and Acceptable Symptom State in PsA
A new study provides evidence of the safety and efficacy of ustekinumab in psoriatic arthritis in a real-world setting.Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 26, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

ACR: IL-12/23 Blocker Offers Long-Term Benefits in SLE
(MedPage Today) -- Responses were sustained out to 1 year with ustekinumab (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - October 24, 2018 Category: Rheumatology Source Type: news

New Phase 2 Data Show Stelara ® (Ustekinumab) Sustained Improvement in Disease Activity in Adults With Systemic Lupus Erythematosus Through One Year
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 23, 2018 Category: Pharmaceuticals Source Type: news